184AA3: a xenograft model of ER+ breast adenocarcinoma
- 549 Downloads
Despite the prevalence and significant morbidity resulting from estrogen receptor positive (ER+) breast adenocarcinomas, there are only a few models of this cancer subtype available for drug development and arguably none for studying etiology. Those models that do exist have questionable clinical relevance. Given our goal of developing luminal models, we focused on six cell lines derived by minimal mutagenesis from normal human breast cells, and asked if any could generate clinically relevant xenografts, which we then extensively characterized. Xenografts of one cell line, 184AA3, consistently formed ER+ adenocarcinomas that had a high proliferative rate and other features consistent with “luminal B” intrinsic subtype. Squamous and spindle cell/mesenchymal differentiation was absent, in stark contrast to other cell lines that we examined or others have reported. We explored intratumoral heterogeneity produced by 184AA3 by immunophenotyping xenograft tumors and cultured cells, and characterized marker expression by immunofluorescence and flow cytometry. A CD44High subpopulation was discovered, yet their tumor forming ability was far less than CD44Low cells. Single cell cloning revealed the phenotypic plasticity of 184AA3, consistent with the intratumoral heterogeneity observed in xenografts. Characterization of ER expression in cultures revealed ER protein and signaling is intact, yet when estrogen was depleted in culture, and in vivo, it did not impact cell or tumor growth, analogous to therapeutically resistant ER+ cancers. This model is appropriate for studies of the etiology of ovarian hormone independent adenocarcinomas, for identification of therapeutic targets, predictive testing, and drug development.
KeywordsLuminal breast cancer models Xenograft Intratumoral heterogeneity Microenvironment
For their invaluable technical assistance during this project, we thank Maria Rojec, Dinah Groesser, Alvin Lo, Sun-Young Lee, Xuefei Tian, and Eva Lee (Lawrence Berkeley National Laboratory). We appreciate also the expertise and help given by Judith Walls and Ed Hubbard (University of California, Davis Center for Comparative Medicine). We express special gratitude also to Michelle Scott of the LBNL flow cytometry and Advanced microscopy facility for her expert technical advice and assistance. Grant support: Innovator award to M.J.B. from the U.S. Department of Defense (W81XWH0810736 and W81XWH12M9532) and in part by National Cancer Institute awards (R37CA064786, R01CA140663, U54CA112970) and by grants from the U.S. Department of Energy, Office of Biological and Environmental Research and Low Dose Scientific Focus Area (Contract No. DE-AC02-05CH1123) and the Breast Cancer Research Foundation. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Compliance with ethical standards
All procedures performed in studies involving animals were in accordance with the ethical standards of the Lawrence Berkeley National Laboratory, at which all such studies were conducted.
Conflicts of interest
The authors declare that they have no conflict of interest.
- 1.Box GE, Draper NR (1987) Empirical model-building and response surfaces, vol 424. Wiley, New YorkGoogle Scholar
- 5.O’Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16(24):6100–6110. doi: 10.1158/1078-0432.CCR-10-1533 PubMedPubMedCentralCrossRefGoogle Scholar
- 7.Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486(7403):353–360. doi: 10.1038/nature11143 PubMedPubMedCentralGoogle Scholar
- 9.Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA (2012) Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat 135(2):415–432. doi: 10.1007/s10549-012-2164-8 PubMedCrossRefGoogle Scholar
- 10.DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17(11):1514–1520. doi: 10.1038/nm.2454 PubMedPubMedCentralCrossRefGoogle Scholar
- 11.Cottu P, Bieche I, Assayag F, El Botty R, Chateau-Joubert S, Thuleau A, Bagarre T, Albaud B, Rapinat A, Gentien D, de la Grange P, Sibut V, Vacher S, Hatem R, Servely JL, Fontaine JJ, Decaudin D, Pierga JY, Roman-Roman S, Marangoni E (2014) Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts. Clin Cancer Res 20(16):4314–4325. doi: 10.1158/1078-0432.CCR-13-3230 PubMedCrossRefGoogle Scholar
- 13.Rizki A, Weaver VM, Lee SY, Rozenberg GI, Chin K, Myers CA, Bascom JL, Mott JD, Semeiks JR, Grate LR, Mian IS, Borowsky AD, Jensen RA, Idowu MO, Chen F, Chen DJ, Petersen OW, Gray JW, Bissell MJ (2008) A human breast cell model of preinvasive to invasive transition. Cancer Res 68(5):1378–1387. doi: 10.1158/0008-5472.CAN-07-2225 PubMedPubMedCentralCrossRefGoogle Scholar
- 15.Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ, Bissell MJ (2006) Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 66(3):1526–1535. doi: 10.1158/0008-5472.CAN-05-3071 PubMedPubMedCentralCrossRefGoogle Scholar
- 26.Biddle A, Gammon L, Fazil B, Mackenzie IC (2013) CD44 staining of cancer stem-like cells is influenced by down-regulation of CD44 variant isoforms and up-regulation of the standard CD44 isoform in the population of cells that have undergone epithelial-to-mesenchymal transition. PLoS One 8(2):e57314. doi: 10.1371/journal.pone.0057314 PubMedPubMedCentralCrossRefGoogle Scholar
- 29.Van Keymeulen A, Lee MY, Ousset M, Brohee S, Rorive S, Giraddi RR, Wuidart A, Bouvencourt G, Dubois C, Salmon I, Sotiriou C, Phillips WA, Blanpain C (2015) Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature 525(7567):119–123. doi: 10.1038/nature14665 PubMedCrossRefGoogle Scholar
- 30.Bissell MJ, Bartholomew JC, Folkman J, Smith H, Stampfer M (1979) Culture systems for studying malignancy. Cancer Res 39:4293–4295Google Scholar
- 32.Thomasset N, Lochter A, Sympson CJ, Lund LR, Williams DR, Behrendtsen O, Werb Z, Bissell MJ (1998) Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. Am J Pathol 153(2):457–467. doi: 10.1016/S0002-9440(10)65589-7 PubMedPubMedCentralCrossRefGoogle Scholar
- 33.Zhang P, Lo A, Huang Y, Huang G, Liang G, Mott J, Karpen GH, Blakely EA, Bissell MJ, Barcellos-Hoff MH, Snijders AM, Mao JH (2015) Identification of genetic loci that control mammary tumor susceptibility through the host microenvironment. Sci Rep 5:8919. doi: 10.1038/srep08919 PubMedPubMedCentralCrossRefGoogle Scholar
- 34.Kim J, Villadsen R, Sorlie T, Fogh L, Gronlund SZ, Fridriksdottir AJ, Kuhn I, Rank F, Wielenga VT, Solvang H, Edwards PA, Borresen-Dale AL, Ronnov-Jessen L, Bissell MJ, Petersen OW (2012) Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity. Proc Natl Acad Sci U S A 109(16):6124–6129. doi: 10.1073/pnas.1203203109 PubMedPubMedCentralCrossRefGoogle Scholar
- 36.Cardiff RD, Hubbard NE, Engelberg JA, Munn RJ, Miller CH, Walls JE, Chen JQ, Velasquez-Garcia HA, Galvez JJ, Bell KJ, Beckett LA, Li YJ, Borowsky AD (2013) Quantitation of fixative-induced morphologic and antigenic variation in mouse and human breast cancers. Lab Invest 93(4):480–497. doi: 10.1038/labinvest.2013.10 PubMedCrossRefGoogle Scholar
- 37.Labarge MA, Garbe JC, Stampfer MR (2013) Processing of human reduction mammoplasty and mastectomy tissues for cell culture. J Vis Exp. doi: 10.3791/50011
- 38.Garbe JC, Bhattacharya S, Merchant B, Bassett E, Swisshelm K, Feiler HS, Wyrobek AJ, Stampfer MR (2009) Molecular distinctions between stasis and telomere attrition senescence barriers shown by long-term culture of normal human mammary epithelial cells. Cancer Res 69(19):7557–7568. doi: 10.1158/0008-5472.CAN-09-0270 PubMedPubMedCentralCrossRefGoogle Scholar
- 39.Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15(8):907–913. doi: 10.1038/nm.2000 PubMedCrossRefGoogle Scholar